Surgeon calls for mandatory vaccination

Article Type
Changed
Fri, 01/18/2019 - 14:27
Display Headline
Surgeon calls for mandatory vaccination

Measles vaccination must be mandatory, Dr. Robert Pearl asserted in an article in Forbes.

There is no effective treatment once children or adults contract measles; patients may experience high fevers and are at risk to develop bronchitis, secondary pneumonia, encephalitis, or hearing damage. They may die, said Dr. Pearl , a plastic and reconstructive surgeon who is CEO of The Permanente Medical Group.

Measles is extremely contagious; its airborne particles can remain infectious for up to 2 hours. Yet 19 states allow personal exemptions for vaccination.

Dr. Pearl stated, “As a society, we don’t condone behavior that puts others at risk for injury or death. There are no exemptions for laws that prohibit drunk driving, for example.

Refusing vaccination for reasons other than a serious medical condition is unfair and dangerous to those who can’t protect themselves. Those who remain unvaccinated pose a great risk to many, including: all children under 1 year old who are too young to be vaccinated, older adults who don’t know their immunity has lapsed, and others with impaired immune systems.”

To read the entire article, go to Forbes Feb. 5, 2015

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
measles, vaccine, mandatory
Sections
Author and Disclosure Information

Author and Disclosure Information

Measles vaccination must be mandatory, Dr. Robert Pearl asserted in an article in Forbes.

There is no effective treatment once children or adults contract measles; patients may experience high fevers and are at risk to develop bronchitis, secondary pneumonia, encephalitis, or hearing damage. They may die, said Dr. Pearl , a plastic and reconstructive surgeon who is CEO of The Permanente Medical Group.

Measles is extremely contagious; its airborne particles can remain infectious for up to 2 hours. Yet 19 states allow personal exemptions for vaccination.

Dr. Pearl stated, “As a society, we don’t condone behavior that puts others at risk for injury or death. There are no exemptions for laws that prohibit drunk driving, for example.

Refusing vaccination for reasons other than a serious medical condition is unfair and dangerous to those who can’t protect themselves. Those who remain unvaccinated pose a great risk to many, including: all children under 1 year old who are too young to be vaccinated, older adults who don’t know their immunity has lapsed, and others with impaired immune systems.”

To read the entire article, go to Forbes Feb. 5, 2015

Measles vaccination must be mandatory, Dr. Robert Pearl asserted in an article in Forbes.

There is no effective treatment once children or adults contract measles; patients may experience high fevers and are at risk to develop bronchitis, secondary pneumonia, encephalitis, or hearing damage. They may die, said Dr. Pearl , a plastic and reconstructive surgeon who is CEO of The Permanente Medical Group.

Measles is extremely contagious; its airborne particles can remain infectious for up to 2 hours. Yet 19 states allow personal exemptions for vaccination.

Dr. Pearl stated, “As a society, we don’t condone behavior that puts others at risk for injury or death. There are no exemptions for laws that prohibit drunk driving, for example.

Refusing vaccination for reasons other than a serious medical condition is unfair and dangerous to those who can’t protect themselves. Those who remain unvaccinated pose a great risk to many, including: all children under 1 year old who are too young to be vaccinated, older adults who don’t know their immunity has lapsed, and others with impaired immune systems.”

To read the entire article, go to Forbes Feb. 5, 2015

References

References

Publications
Publications
Topics
Article Type
Display Headline
Surgeon calls for mandatory vaccination
Display Headline
Surgeon calls for mandatory vaccination
Legacy Keywords
measles, vaccine, mandatory
Legacy Keywords
measles, vaccine, mandatory
Sections
Article Source

PURLs Copyright

Inside the Article

NYU ethicist: Revoke licenses of antivaccination doctors

Article Type
Changed
Fri, 01/18/2019 - 14:27
Display Headline
NYU ethicist: Revoke licenses of antivaccination doctors

Physicians who espouse views based on anecdotes, myths, or ideology, especially in the middle of an epidemic, should have their medical licenses revoked, said Arthur L. Caplan, director of the division of medical ethics at New York University Langone Medical Center’s department of population health.

In a commentary about measles vaccination in The Washington Post, Mr. Caplan outlined in detail why three physicians who have made public their views against vaccination can and should lose their medical licenses, in his opinion.

A doctor is held to a higher standard than the average person, and “must consider the public health and the patient good in all that he says in his role as expert. To do otherwise ... is unprofessional. It might even constitute misconduct if it contributed to an epidemic. Counseling against vaccination is exactly that kind of misconduct,” he said.

To read the entire article, go to: The Washington Post, Feb. 7, 2015.

*Correction, 2/19/2015: An earlier version of this article carried a headline that misstated Dr. Kaplan’s profession.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
measles, vaccine, revoke, medical license
Sections
Author and Disclosure Information

Author and Disclosure Information

Physicians who espouse views based on anecdotes, myths, or ideology, especially in the middle of an epidemic, should have their medical licenses revoked, said Arthur L. Caplan, director of the division of medical ethics at New York University Langone Medical Center’s department of population health.

In a commentary about measles vaccination in The Washington Post, Mr. Caplan outlined in detail why three physicians who have made public their views against vaccination can and should lose their medical licenses, in his opinion.

A doctor is held to a higher standard than the average person, and “must consider the public health and the patient good in all that he says in his role as expert. To do otherwise ... is unprofessional. It might even constitute misconduct if it contributed to an epidemic. Counseling against vaccination is exactly that kind of misconduct,” he said.

To read the entire article, go to: The Washington Post, Feb. 7, 2015.

*Correction, 2/19/2015: An earlier version of this article carried a headline that misstated Dr. Kaplan’s profession.

Physicians who espouse views based on anecdotes, myths, or ideology, especially in the middle of an epidemic, should have their medical licenses revoked, said Arthur L. Caplan, director of the division of medical ethics at New York University Langone Medical Center’s department of population health.

In a commentary about measles vaccination in The Washington Post, Mr. Caplan outlined in detail why three physicians who have made public their views against vaccination can and should lose their medical licenses, in his opinion.

A doctor is held to a higher standard than the average person, and “must consider the public health and the patient good in all that he says in his role as expert. To do otherwise ... is unprofessional. It might even constitute misconduct if it contributed to an epidemic. Counseling against vaccination is exactly that kind of misconduct,” he said.

To read the entire article, go to: The Washington Post, Feb. 7, 2015.

*Correction, 2/19/2015: An earlier version of this article carried a headline that misstated Dr. Kaplan’s profession.

References

References

Publications
Publications
Topics
Article Type
Display Headline
NYU ethicist: Revoke licenses of antivaccination doctors
Display Headline
NYU ethicist: Revoke licenses of antivaccination doctors
Legacy Keywords
measles, vaccine, revoke, medical license
Legacy Keywords
measles, vaccine, revoke, medical license
Sections
Article Source

PURLs Copyright

Inside the Article

Saying thank you to patients

Article Type
Changed
Fri, 01/18/2019 - 14:26
Display Headline
Saying thank you to patients

I say “Thank you” a lot to patients. And I mean it.

I like being a doctor. It’s something I always wanted to do. For all the difficulties that go along with it, I still enjoy the actual job of caring for those who come to me. They’re the reason I’m here, and they keep my practice afloat and let me do what I want in life.

Like any other business, I have competitors. In my area, people have a choice of neurologists, and I appreciate that they picked me. So I always try to thank them when walking up to checkout.

A big part of what makes the job rewarding are those who feel the same way about me. It’s always nice when they thank me for helping, or trying to help, or just listening. I try to be a good doctor, so I’m glad to have someone recognize that. In this field, you can’t make everyone happy, but if I can have a solid majority who understand that I’m doing my best for them, I’ll take it.

I’m not fishing for compliments, or gifts, or a parade. Experience has taught me that patients who are overly flattering are most likely not to mean it. If someone calls me too many wonderful things, I immediately worry about their ulterior motives. Are they looking for narcotics? Disability? A legal action?

But a simple, sincere, “Thank you” from a patient can make it all worthwhile. Even on a bad day, it’s still a bright spot. It’s nice to know I’m making a difference. When I get a small note or appreciative Christmas card from a patient, I save it. They go in a drawer to be taken out and read after a particularly rough time, to remind myself that I must be doing something right.

Being appreciated reminds me why I’m here, and that this was the right choice for me. It lets me know that I’m doing what I set out to do many years ago: to help people.

Dr. Block has a solo neurology practice in Scottsdale, Ariz.

References

Author and Disclosure Information

Publications
Legacy Keywords
neurology, patients, appreciation
Sections
Author and Disclosure Information

Author and Disclosure Information

I say “Thank you” a lot to patients. And I mean it.

I like being a doctor. It’s something I always wanted to do. For all the difficulties that go along with it, I still enjoy the actual job of caring for those who come to me. They’re the reason I’m here, and they keep my practice afloat and let me do what I want in life.

Like any other business, I have competitors. In my area, people have a choice of neurologists, and I appreciate that they picked me. So I always try to thank them when walking up to checkout.

A big part of what makes the job rewarding are those who feel the same way about me. It’s always nice when they thank me for helping, or trying to help, or just listening. I try to be a good doctor, so I’m glad to have someone recognize that. In this field, you can’t make everyone happy, but if I can have a solid majority who understand that I’m doing my best for them, I’ll take it.

I’m not fishing for compliments, or gifts, or a parade. Experience has taught me that patients who are overly flattering are most likely not to mean it. If someone calls me too many wonderful things, I immediately worry about their ulterior motives. Are they looking for narcotics? Disability? A legal action?

But a simple, sincere, “Thank you” from a patient can make it all worthwhile. Even on a bad day, it’s still a bright spot. It’s nice to know I’m making a difference. When I get a small note or appreciative Christmas card from a patient, I save it. They go in a drawer to be taken out and read after a particularly rough time, to remind myself that I must be doing something right.

Being appreciated reminds me why I’m here, and that this was the right choice for me. It lets me know that I’m doing what I set out to do many years ago: to help people.

Dr. Block has a solo neurology practice in Scottsdale, Ariz.

I say “Thank you” a lot to patients. And I mean it.

I like being a doctor. It’s something I always wanted to do. For all the difficulties that go along with it, I still enjoy the actual job of caring for those who come to me. They’re the reason I’m here, and they keep my practice afloat and let me do what I want in life.

Like any other business, I have competitors. In my area, people have a choice of neurologists, and I appreciate that they picked me. So I always try to thank them when walking up to checkout.

A big part of what makes the job rewarding are those who feel the same way about me. It’s always nice when they thank me for helping, or trying to help, or just listening. I try to be a good doctor, so I’m glad to have someone recognize that. In this field, you can’t make everyone happy, but if I can have a solid majority who understand that I’m doing my best for them, I’ll take it.

I’m not fishing for compliments, or gifts, or a parade. Experience has taught me that patients who are overly flattering are most likely not to mean it. If someone calls me too many wonderful things, I immediately worry about their ulterior motives. Are they looking for narcotics? Disability? A legal action?

But a simple, sincere, “Thank you” from a patient can make it all worthwhile. Even on a bad day, it’s still a bright spot. It’s nice to know I’m making a difference. When I get a small note or appreciative Christmas card from a patient, I save it. They go in a drawer to be taken out and read after a particularly rough time, to remind myself that I must be doing something right.

Being appreciated reminds me why I’m here, and that this was the right choice for me. It lets me know that I’m doing what I set out to do many years ago: to help people.

Dr. Block has a solo neurology practice in Scottsdale, Ariz.

References

References

Publications
Publications
Article Type
Display Headline
Saying thank you to patients
Display Headline
Saying thank you to patients
Legacy Keywords
neurology, patients, appreciation
Legacy Keywords
neurology, patients, appreciation
Sections
Article Source

PURLs Copyright

Inside the Article

A mom-ent to comment

Article Type
Changed
Fri, 01/18/2019 - 14:26
Display Headline
A mom-ent to comment

I read your Letters From Maine column entitled “A defining Mom-ent” with humor and, admittedly, a bit of disbelief. First, allow me to say, I am glad that in 2014, you are sharing and encouraging this mom-ent of awareness. I hope you will also allow me to say, “Really?! It is almost 2015” – (said with humor and exhaustion!)

I am a woman who also is a daughter, wife, parent of two children, pediatrician, and trustee on a foundation. I had the experience of having a pediatrician walk into my hospital room after delivering our youngest child, 4 years ago, and calling me “mother.” It was jarring. I thought to myself, “I am not your mother. Why are you calling me Mom?” I was so tired from having given birth that I did not have the energy to address the complete and utter amazement that term carried at that moment.

Later, it occurred to me that female pediatricians never referred to me as “Mom.” In fact, they referred to me by my name – such a welcome sound after being called everything but my name for days while I recovered from my cesarean section.

Really, what your column is about is that maybe male pediatricians are beginning to realize that assumptions some have made about how to address women who have added the additional facet of motherhood to their identity have known for a long time – we are more than what we do. Women who are physicians and mothers have been aware of this dynamic for a long time.

Kudos to you for being public about your realization and let it also be a call to all pediatricians to check their assumptions and how those assumptions are communicated through language. I think we should all be willing to humbly ask our patients, “What is your preferred name?” It is an icebreaker that imparts respect, humbleness, and kindness in one fell swoop. Thank you again for your thoughts.

Bernetta L. Avery, M.D.

Portland, Ore.

Dr. Wilkoff responds: Great e-mail. I like your suggestion of the icebreaker. I think with your advice I would (if I were still practicing) change my opening line to something like yours. I think it helps a lot of us do the best thing.

 

 

The beauty of motherhood 

I just finished reading your article about calling a woman who recently delivered a baby, “Mom.” I appreciate that this is a common scenario for some pediatricians, although I have not had any issue with this and find it very disturbing. As a pediatrician, a wife, an active member of my community, and also a mom, I am happy being called any of those titles. I feel that our society has taken away the beauty of motherhood in so many ways – from politicians assuming that all women voters care about is reproductive rights, to now insulting someone by referring to her as “mom” right after she delivered a baby! She can be insulted all she wants, but the fact is, she is now a mom. And always will be! Very few women are “just” moms, but rather have other interests and skills beyond motherhood. But to assume that by us calling a new mother “Mom,” we are insulting them, is really an insult to motherhood everywhere. I will not change my practice of how I interact with families, but rather will celebrate with these new families and call them by their rightful new “names” – Mom and Dad.

Thank you for the article.

Kathryn M. Cambi, M.D.

Hamden, Conn.

Dr. Wilkoff responds: I received an e-mail from another mother/pediatrician (see above), who after the birth of her first child had a similar experience to the one I related in the column. Although she was troubled, it was not to the degree as the woman I referred to. She said that when she introduces herself, she asks the new mother how she would like to be addressed. I guess that is a reasonable approach, but I agree with you, it is sad that she feels that tip-toeing around the label of motherhood is necessary. I’m glad you are proud to wear the label of “Mom.”

 

 

Too lazy

I am a western New York pediatrician in my 25th year of practice, and I find your columns both interesting and down to earth. However, I think your “A defining Mom-ent” column misses an important point.

My path to medicine was circuitous, and I began medical school with a 5-year-old daughter, delivered my second child at the beginning of the third year of medical school, and my third child was born a week after finishing my residency. I was a “multifaceted” (as you say), although somewhat different individual at each of these deliveries, and at each one, I was referred to as “Mom” by a variety of medical personnel – nurses and physicians alike. Each time was uncomfortable, not because I felt my identity was not defined by motherhood alone, but because it appeared that either the individual using the title had been too lazy to check the chart for my name and/or because the use of that title by that individual seemed at best inappropriate and at worst condescending.

“Mom” is both a word and a title (hence capitalized when a title and not when used as a noun) and, as a title, has limited appropriate use. Only my daughters have the right to call me “Mom.”

I ask you, Dr. Wilkoff, how would you feel if the young check-out person at your grocery store concluded your transaction with, “Have a great day, Gramps.”?

Dolores C. Leonard, M.D. (also “Mom” and “Grandma” to select people)

Buffalo

Dr. Wilkoff responds: I received two previous letters from female pediatricians, one who shares your view and experience and one who is untroubled by the issue. I think your point about the inappropriate familiarity is spot on, but clearly the woman who wrote the original letter to the New York Times was having trouble with her identity, a problem that neither you nor the other responders to my column seem to share. Thanks for writing and thanks more for responding.

References

Author and Disclosure Information

Publications
Legacy Keywords
mom, mothers, babies, pediatricians, identity, familiarity
Sections
Author and Disclosure Information

Author and Disclosure Information

I read your Letters From Maine column entitled “A defining Mom-ent” with humor and, admittedly, a bit of disbelief. First, allow me to say, I am glad that in 2014, you are sharing and encouraging this mom-ent of awareness. I hope you will also allow me to say, “Really?! It is almost 2015” – (said with humor and exhaustion!)

I am a woman who also is a daughter, wife, parent of two children, pediatrician, and trustee on a foundation. I had the experience of having a pediatrician walk into my hospital room after delivering our youngest child, 4 years ago, and calling me “mother.” It was jarring. I thought to myself, “I am not your mother. Why are you calling me Mom?” I was so tired from having given birth that I did not have the energy to address the complete and utter amazement that term carried at that moment.

Later, it occurred to me that female pediatricians never referred to me as “Mom.” In fact, they referred to me by my name – such a welcome sound after being called everything but my name for days while I recovered from my cesarean section.

Really, what your column is about is that maybe male pediatricians are beginning to realize that assumptions some have made about how to address women who have added the additional facet of motherhood to their identity have known for a long time – we are more than what we do. Women who are physicians and mothers have been aware of this dynamic for a long time.

Kudos to you for being public about your realization and let it also be a call to all pediatricians to check their assumptions and how those assumptions are communicated through language. I think we should all be willing to humbly ask our patients, “What is your preferred name?” It is an icebreaker that imparts respect, humbleness, and kindness in one fell swoop. Thank you again for your thoughts.

Bernetta L. Avery, M.D.

Portland, Ore.

Dr. Wilkoff responds: Great e-mail. I like your suggestion of the icebreaker. I think with your advice I would (if I were still practicing) change my opening line to something like yours. I think it helps a lot of us do the best thing.

 

 

The beauty of motherhood 

I just finished reading your article about calling a woman who recently delivered a baby, “Mom.” I appreciate that this is a common scenario for some pediatricians, although I have not had any issue with this and find it very disturbing. As a pediatrician, a wife, an active member of my community, and also a mom, I am happy being called any of those titles. I feel that our society has taken away the beauty of motherhood in so many ways – from politicians assuming that all women voters care about is reproductive rights, to now insulting someone by referring to her as “mom” right after she delivered a baby! She can be insulted all she wants, but the fact is, she is now a mom. And always will be! Very few women are “just” moms, but rather have other interests and skills beyond motherhood. But to assume that by us calling a new mother “Mom,” we are insulting them, is really an insult to motherhood everywhere. I will not change my practice of how I interact with families, but rather will celebrate with these new families and call them by their rightful new “names” – Mom and Dad.

Thank you for the article.

Kathryn M. Cambi, M.D.

Hamden, Conn.

Dr. Wilkoff responds: I received an e-mail from another mother/pediatrician (see above), who after the birth of her first child had a similar experience to the one I related in the column. Although she was troubled, it was not to the degree as the woman I referred to. She said that when she introduces herself, she asks the new mother how she would like to be addressed. I guess that is a reasonable approach, but I agree with you, it is sad that she feels that tip-toeing around the label of motherhood is necessary. I’m glad you are proud to wear the label of “Mom.”

 

 

Too lazy

I am a western New York pediatrician in my 25th year of practice, and I find your columns both interesting and down to earth. However, I think your “A defining Mom-ent” column misses an important point.

My path to medicine was circuitous, and I began medical school with a 5-year-old daughter, delivered my second child at the beginning of the third year of medical school, and my third child was born a week after finishing my residency. I was a “multifaceted” (as you say), although somewhat different individual at each of these deliveries, and at each one, I was referred to as “Mom” by a variety of medical personnel – nurses and physicians alike. Each time was uncomfortable, not because I felt my identity was not defined by motherhood alone, but because it appeared that either the individual using the title had been too lazy to check the chart for my name and/or because the use of that title by that individual seemed at best inappropriate and at worst condescending.

“Mom” is both a word and a title (hence capitalized when a title and not when used as a noun) and, as a title, has limited appropriate use. Only my daughters have the right to call me “Mom.”

I ask you, Dr. Wilkoff, how would you feel if the young check-out person at your grocery store concluded your transaction with, “Have a great day, Gramps.”?

Dolores C. Leonard, M.D. (also “Mom” and “Grandma” to select people)

Buffalo

Dr. Wilkoff responds: I received two previous letters from female pediatricians, one who shares your view and experience and one who is untroubled by the issue. I think your point about the inappropriate familiarity is spot on, but clearly the woman who wrote the original letter to the New York Times was having trouble with her identity, a problem that neither you nor the other responders to my column seem to share. Thanks for writing and thanks more for responding.

I read your Letters From Maine column entitled “A defining Mom-ent” with humor and, admittedly, a bit of disbelief. First, allow me to say, I am glad that in 2014, you are sharing and encouraging this mom-ent of awareness. I hope you will also allow me to say, “Really?! It is almost 2015” – (said with humor and exhaustion!)

I am a woman who also is a daughter, wife, parent of two children, pediatrician, and trustee on a foundation. I had the experience of having a pediatrician walk into my hospital room after delivering our youngest child, 4 years ago, and calling me “mother.” It was jarring. I thought to myself, “I am not your mother. Why are you calling me Mom?” I was so tired from having given birth that I did not have the energy to address the complete and utter amazement that term carried at that moment.

Later, it occurred to me that female pediatricians never referred to me as “Mom.” In fact, they referred to me by my name – such a welcome sound after being called everything but my name for days while I recovered from my cesarean section.

Really, what your column is about is that maybe male pediatricians are beginning to realize that assumptions some have made about how to address women who have added the additional facet of motherhood to their identity have known for a long time – we are more than what we do. Women who are physicians and mothers have been aware of this dynamic for a long time.

Kudos to you for being public about your realization and let it also be a call to all pediatricians to check their assumptions and how those assumptions are communicated through language. I think we should all be willing to humbly ask our patients, “What is your preferred name?” It is an icebreaker that imparts respect, humbleness, and kindness in one fell swoop. Thank you again for your thoughts.

Bernetta L. Avery, M.D.

Portland, Ore.

Dr. Wilkoff responds: Great e-mail. I like your suggestion of the icebreaker. I think with your advice I would (if I were still practicing) change my opening line to something like yours. I think it helps a lot of us do the best thing.

 

 

The beauty of motherhood 

I just finished reading your article about calling a woman who recently delivered a baby, “Mom.” I appreciate that this is a common scenario for some pediatricians, although I have not had any issue with this and find it very disturbing. As a pediatrician, a wife, an active member of my community, and also a mom, I am happy being called any of those titles. I feel that our society has taken away the beauty of motherhood in so many ways – from politicians assuming that all women voters care about is reproductive rights, to now insulting someone by referring to her as “mom” right after she delivered a baby! She can be insulted all she wants, but the fact is, she is now a mom. And always will be! Very few women are “just” moms, but rather have other interests and skills beyond motherhood. But to assume that by us calling a new mother “Mom,” we are insulting them, is really an insult to motherhood everywhere. I will not change my practice of how I interact with families, but rather will celebrate with these new families and call them by their rightful new “names” – Mom and Dad.

Thank you for the article.

Kathryn M. Cambi, M.D.

Hamden, Conn.

Dr. Wilkoff responds: I received an e-mail from another mother/pediatrician (see above), who after the birth of her first child had a similar experience to the one I related in the column. Although she was troubled, it was not to the degree as the woman I referred to. She said that when she introduces herself, she asks the new mother how she would like to be addressed. I guess that is a reasonable approach, but I agree with you, it is sad that she feels that tip-toeing around the label of motherhood is necessary. I’m glad you are proud to wear the label of “Mom.”

 

 

Too lazy

I am a western New York pediatrician in my 25th year of practice, and I find your columns both interesting and down to earth. However, I think your “A defining Mom-ent” column misses an important point.

My path to medicine was circuitous, and I began medical school with a 5-year-old daughter, delivered my second child at the beginning of the third year of medical school, and my third child was born a week after finishing my residency. I was a “multifaceted” (as you say), although somewhat different individual at each of these deliveries, and at each one, I was referred to as “Mom” by a variety of medical personnel – nurses and physicians alike. Each time was uncomfortable, not because I felt my identity was not defined by motherhood alone, but because it appeared that either the individual using the title had been too lazy to check the chart for my name and/or because the use of that title by that individual seemed at best inappropriate and at worst condescending.

“Mom” is both a word and a title (hence capitalized when a title and not when used as a noun) and, as a title, has limited appropriate use. Only my daughters have the right to call me “Mom.”

I ask you, Dr. Wilkoff, how would you feel if the young check-out person at your grocery store concluded your transaction with, “Have a great day, Gramps.”?

Dolores C. Leonard, M.D. (also “Mom” and “Grandma” to select people)

Buffalo

Dr. Wilkoff responds: I received two previous letters from female pediatricians, one who shares your view and experience and one who is untroubled by the issue. I think your point about the inappropriate familiarity is spot on, but clearly the woman who wrote the original letter to the New York Times was having trouble with her identity, a problem that neither you nor the other responders to my column seem to share. Thanks for writing and thanks more for responding.

References

References

Publications
Publications
Article Type
Display Headline
A mom-ent to comment
Display Headline
A mom-ent to comment
Legacy Keywords
mom, mothers, babies, pediatricians, identity, familiarity
Legacy Keywords
mom, mothers, babies, pediatricians, identity, familiarity
Sections
Article Source

PURLs Copyright

Inside the Article

Fearful pictures

Article Type
Changed
Fri, 01/18/2019 - 14:26
Display Headline
Fearful pictures

As the recent measles outbreak spreads out from its apparent epicenter at Disneyland Resorts in California, the media spotlights have again swung to the problem of underimmunization and the effect of vaccine refusal by parents. Because the statistics that are so alarming to us as pediatricians have little audience-grabbing appeal for print and electronic journalists, nearly every story about immunizations includes a picture of a young child screaming in pain and/or horror as he or she is receiving or is about to receive an injection.

In the Wall Street Journal, I was assaulted by one of the more egregious examples of this kind of inflammatory and fear-mongering photojournalism. The four-column-wide image depicts a cute 10- to 12-month old boy sitting in his mother’s lap encircled by her ample arms. He is grimacing, eyes puffed from crying as he is receives an injection in his left upper arm. You know he is about to shriek and the pacifier will fall out of his mouth. His mother is also grimacing, her teeth bared. Her eyes are clenched closed as she turns away from the horror.

Joe Raedle/Getty Images

The villain in this scene could be the young woman clothed in a lab coat and wearing blue plastic gloves. Of course, it isn’t much of a leap to believe that the real villain is the syringe and the vaccine it contains. A closer look at the image reveals the thumb of a gloved hand that is holding the little victim’s left leg. His puffy eyes suggest that this moment is the culmination of a long and unpleasant preamble.

Of course, the first and most important question we must ask is why does the media persist in using these anxiety-provoking images to embellish otherwise evenhanded and well-written stories about vaccine refusal? You might defend the journalists by pointing out that kids often cry when they get shots and that it is hard to find images of a contented child receiving an injection. Baloney!

© Sean Locke/iStockphoto.com
A cheerful physician giving a vaccine to a nervous -- but not crying -- little girl.

I have just done a quick Google image search of “children receiving immunizations,” and what I found in scrolling down the first 45 photos of children receiving injections was that only five were crying – seven, in fact, were smiling! The rest had neutral facial expressions and body postures.

I saw a picture of the same white-coated injector in the New York Times. This time, the victim was girl about age 2 years, in full scream, sitting on her mother’s lap, her right arm pinned by her mother and an ungloved fully visible pink-printed grandmotherly assistant. The injector’s face revealed more than a trace of anxiety. Both these images were attributed to Getty Images and were probably from the same photo shoot. Obviously, the editors responsible for these stories hadn’t looked very hard for a photograph that might portray immunizations in a more-positive light.

 

 

Much has been written lately about religious and antiscience (or at least junk science) aspects of vaccine refusal. I don’t recall seeing much, if anything, said about just plain old needle fear. I suspect that many vaccine decliners are hiding (consciously or unconsciously) their fear of injections under the cloak of “intellectual” or religious choice. By continuing to use the kinds of fear-mongering images I have described, journalists are fueling the vaccine refusal debate.

How about you and I who provide immunizations on a regular basis adopt a policy of refusing to allow pictures from our offices to be taken immunizing uncooperative or terrified children? Or at least journalists should be forced publish three images of contented vaccine recipients for every photograph of a screaming child. Or, even better, how about a one-for-one arrangement that shows one child in the intensive care unit as the result of a vaccine-preventable illness for every crying injection recipient?

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics, including “How to Say No to Your Toddler.” E-mail him at [email protected].

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
vaccine, measles, photojournalism, vaccines, shots, fear, crying
Sections
Author and Disclosure Information

Author and Disclosure Information

As the recent measles outbreak spreads out from its apparent epicenter at Disneyland Resorts in California, the media spotlights have again swung to the problem of underimmunization and the effect of vaccine refusal by parents. Because the statistics that are so alarming to us as pediatricians have little audience-grabbing appeal for print and electronic journalists, nearly every story about immunizations includes a picture of a young child screaming in pain and/or horror as he or she is receiving or is about to receive an injection.

In the Wall Street Journal, I was assaulted by one of the more egregious examples of this kind of inflammatory and fear-mongering photojournalism. The four-column-wide image depicts a cute 10- to 12-month old boy sitting in his mother’s lap encircled by her ample arms. He is grimacing, eyes puffed from crying as he is receives an injection in his left upper arm. You know he is about to shriek and the pacifier will fall out of his mouth. His mother is also grimacing, her teeth bared. Her eyes are clenched closed as she turns away from the horror.

Joe Raedle/Getty Images

The villain in this scene could be the young woman clothed in a lab coat and wearing blue plastic gloves. Of course, it isn’t much of a leap to believe that the real villain is the syringe and the vaccine it contains. A closer look at the image reveals the thumb of a gloved hand that is holding the little victim’s left leg. His puffy eyes suggest that this moment is the culmination of a long and unpleasant preamble.

Of course, the first and most important question we must ask is why does the media persist in using these anxiety-provoking images to embellish otherwise evenhanded and well-written stories about vaccine refusal? You might defend the journalists by pointing out that kids often cry when they get shots and that it is hard to find images of a contented child receiving an injection. Baloney!

© Sean Locke/iStockphoto.com
A cheerful physician giving a vaccine to a nervous -- but not crying -- little girl.

I have just done a quick Google image search of “children receiving immunizations,” and what I found in scrolling down the first 45 photos of children receiving injections was that only five were crying – seven, in fact, were smiling! The rest had neutral facial expressions and body postures.

I saw a picture of the same white-coated injector in the New York Times. This time, the victim was girl about age 2 years, in full scream, sitting on her mother’s lap, her right arm pinned by her mother and an ungloved fully visible pink-printed grandmotherly assistant. The injector’s face revealed more than a trace of anxiety. Both these images were attributed to Getty Images and were probably from the same photo shoot. Obviously, the editors responsible for these stories hadn’t looked very hard for a photograph that might portray immunizations in a more-positive light.

 

 

Much has been written lately about religious and antiscience (or at least junk science) aspects of vaccine refusal. I don’t recall seeing much, if anything, said about just plain old needle fear. I suspect that many vaccine decliners are hiding (consciously or unconsciously) their fear of injections under the cloak of “intellectual” or religious choice. By continuing to use the kinds of fear-mongering images I have described, journalists are fueling the vaccine refusal debate.

How about you and I who provide immunizations on a regular basis adopt a policy of refusing to allow pictures from our offices to be taken immunizing uncooperative or terrified children? Or at least journalists should be forced publish three images of contented vaccine recipients for every photograph of a screaming child. Or, even better, how about a one-for-one arrangement that shows one child in the intensive care unit as the result of a vaccine-preventable illness for every crying injection recipient?

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics, including “How to Say No to Your Toddler.” E-mail him at [email protected].

As the recent measles outbreak spreads out from its apparent epicenter at Disneyland Resorts in California, the media spotlights have again swung to the problem of underimmunization and the effect of vaccine refusal by parents. Because the statistics that are so alarming to us as pediatricians have little audience-grabbing appeal for print and electronic journalists, nearly every story about immunizations includes a picture of a young child screaming in pain and/or horror as he or she is receiving or is about to receive an injection.

In the Wall Street Journal, I was assaulted by one of the more egregious examples of this kind of inflammatory and fear-mongering photojournalism. The four-column-wide image depicts a cute 10- to 12-month old boy sitting in his mother’s lap encircled by her ample arms. He is grimacing, eyes puffed from crying as he is receives an injection in his left upper arm. You know he is about to shriek and the pacifier will fall out of his mouth. His mother is also grimacing, her teeth bared. Her eyes are clenched closed as she turns away from the horror.

Joe Raedle/Getty Images

The villain in this scene could be the young woman clothed in a lab coat and wearing blue plastic gloves. Of course, it isn’t much of a leap to believe that the real villain is the syringe and the vaccine it contains. A closer look at the image reveals the thumb of a gloved hand that is holding the little victim’s left leg. His puffy eyes suggest that this moment is the culmination of a long and unpleasant preamble.

Of course, the first and most important question we must ask is why does the media persist in using these anxiety-provoking images to embellish otherwise evenhanded and well-written stories about vaccine refusal? You might defend the journalists by pointing out that kids often cry when they get shots and that it is hard to find images of a contented child receiving an injection. Baloney!

© Sean Locke/iStockphoto.com
A cheerful physician giving a vaccine to a nervous -- but not crying -- little girl.

I have just done a quick Google image search of “children receiving immunizations,” and what I found in scrolling down the first 45 photos of children receiving injections was that only five were crying – seven, in fact, were smiling! The rest had neutral facial expressions and body postures.

I saw a picture of the same white-coated injector in the New York Times. This time, the victim was girl about age 2 years, in full scream, sitting on her mother’s lap, her right arm pinned by her mother and an ungloved fully visible pink-printed grandmotherly assistant. The injector’s face revealed more than a trace of anxiety. Both these images were attributed to Getty Images and were probably from the same photo shoot. Obviously, the editors responsible for these stories hadn’t looked very hard for a photograph that might portray immunizations in a more-positive light.

 

 

Much has been written lately about religious and antiscience (or at least junk science) aspects of vaccine refusal. I don’t recall seeing much, if anything, said about just plain old needle fear. I suspect that many vaccine decliners are hiding (consciously or unconsciously) their fear of injections under the cloak of “intellectual” or religious choice. By continuing to use the kinds of fear-mongering images I have described, journalists are fueling the vaccine refusal debate.

How about you and I who provide immunizations on a regular basis adopt a policy of refusing to allow pictures from our offices to be taken immunizing uncooperative or terrified children? Or at least journalists should be forced publish three images of contented vaccine recipients for every photograph of a screaming child. Or, even better, how about a one-for-one arrangement that shows one child in the intensive care unit as the result of a vaccine-preventable illness for every crying injection recipient?

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics, including “How to Say No to Your Toddler.” E-mail him at [email protected].

References

References

Publications
Publications
Topics
Article Type
Display Headline
Fearful pictures
Display Headline
Fearful pictures
Legacy Keywords
vaccine, measles, photojournalism, vaccines, shots, fear, crying
Legacy Keywords
vaccine, measles, photojournalism, vaccines, shots, fear, crying
Sections
Article Source

PURLs Copyright

Inside the Article

Snot happens

Article Type
Changed
Fri, 01/18/2019 - 14:26
Display Headline
Snot happens

If you do your recreational reading during your lunch break, you might want to skip this column and save it for later in the day because I’m going to be talking about snot ... gooey, slimy, green, yellow, and even clear, runny snot. Children and snot go together like ham and eggs.

Although snot is as much a part of the normal maturation process as cutting and losing primary teeth, it suffers from a serious image problem. When we refer to a “snotty-nosed kid,” we aren’t just describing a child with an unappealing visage – we are suggesting that he has a personality problem and an unpleasant demeanor. But, this characterization is unfairly inaccurate because during the winter months, it seems that 90% of the children under the age of 3 years have runny, snotty noses. Most of them continue to be cute and have endearing personalities despite the river of mucus cascading down over their upper lips.

Adults may complain of having a “runny nose,” but they would never admit to having a “snotty nose.” Does something magically happen at puberty so that the human body no longer manufactures snot? No, it is all about appearances. Adults have learned strategies for keeping snot off their faces. They carry handkerchiefs in their pockets or wads of facial tissue stuffed up a sleeve.

But little children don’t care how they look. Like tears, snot emerges on their faces at body temperature. It doesn’t feel uncomfortable and when it drips from their upper lips and lands on their tongue, it doesn’t taste unpleasant. Little children don’t have important paperwork that might be spattered with dripping snot nor do they have computer keyboards or touch screens to be besmirched (or at least they shouldn’t have).

The fact is that adults, especially parents, don’t like the look of snot dripping from anyone’s nose. They don’t even like the sound of it gurgling around that might signal the appearance of a disgusting rivulet. I recently learned from an article in the Wall Street Journal (“Clear Baby’s Stuffy Nose,” by Laura Johannes, Feb 2, 2015) about two new products that promise parents a new tool to deal with this natural substance that they find so repulsive. Both gadgets incorporate a mouthpiece and tube with which the parent or caregiver sucks the snot out of the child’s nose into a reservoir. Although each system is fitted with a filter of sorts, I doubt you will find many nonparental caregivers logging on to watch the instructional videos.

A small study reported by one of the manufacturers claims that parents felt that their children were less congested and slept better when they used these “snotsuckers.” Of course, there was no control group. I suspect that neither apparatus would be any more effective that the old blue, green or brown suction bulb that seems to magically emerge from the womb immediately after the baby and before the placenta. At least I’ve always assumed that’s where they came from because one always appeared on the warming /resuscitation table wrapped in the same towel as the baby.

These little one-piece wonders with no moving parts to malfunction or detach are all one needs to remove snot ... that is, if it needs to be removed. The problem with rubber bulbs is that if used too often they can cause irritation of the nares. However, it you can convince parents to use a bulb only when the child is experiencing some trouble breathing, this complication is usually avoided. The challenge is getting parents to ignore their natural revulsion to seeing or even hearing snot. Trying to make their child’s face a snot-free zone will make the child’s nose a bloody painful mess.

The same challenge will confront you if you suggest to parents that their child will be more comfortable if they wipe his runny nose as infrequently as possible. It seems too counterintuitive that the best option for the child is to let the snot dry on and soak it off with warm water at lunch, bedtime, and of course, just before Skyping with Grandma.

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics, including “Coping with a Picky Eater.” E-mail him at [email protected].

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
snot, nares, bulb, runny nose, mucus, snotty-nosed kid
Sections
Author and Disclosure Information

Author and Disclosure Information

If you do your recreational reading during your lunch break, you might want to skip this column and save it for later in the day because I’m going to be talking about snot ... gooey, slimy, green, yellow, and even clear, runny snot. Children and snot go together like ham and eggs.

Although snot is as much a part of the normal maturation process as cutting and losing primary teeth, it suffers from a serious image problem. When we refer to a “snotty-nosed kid,” we aren’t just describing a child with an unappealing visage – we are suggesting that he has a personality problem and an unpleasant demeanor. But, this characterization is unfairly inaccurate because during the winter months, it seems that 90% of the children under the age of 3 years have runny, snotty noses. Most of them continue to be cute and have endearing personalities despite the river of mucus cascading down over their upper lips.

Adults may complain of having a “runny nose,” but they would never admit to having a “snotty nose.” Does something magically happen at puberty so that the human body no longer manufactures snot? No, it is all about appearances. Adults have learned strategies for keeping snot off their faces. They carry handkerchiefs in their pockets or wads of facial tissue stuffed up a sleeve.

But little children don’t care how they look. Like tears, snot emerges on their faces at body temperature. It doesn’t feel uncomfortable and when it drips from their upper lips and lands on their tongue, it doesn’t taste unpleasant. Little children don’t have important paperwork that might be spattered with dripping snot nor do they have computer keyboards or touch screens to be besmirched (or at least they shouldn’t have).

The fact is that adults, especially parents, don’t like the look of snot dripping from anyone’s nose. They don’t even like the sound of it gurgling around that might signal the appearance of a disgusting rivulet. I recently learned from an article in the Wall Street Journal (“Clear Baby’s Stuffy Nose,” by Laura Johannes, Feb 2, 2015) about two new products that promise parents a new tool to deal with this natural substance that they find so repulsive. Both gadgets incorporate a mouthpiece and tube with which the parent or caregiver sucks the snot out of the child’s nose into a reservoir. Although each system is fitted with a filter of sorts, I doubt you will find many nonparental caregivers logging on to watch the instructional videos.

A small study reported by one of the manufacturers claims that parents felt that their children were less congested and slept better when they used these “snotsuckers.” Of course, there was no control group. I suspect that neither apparatus would be any more effective that the old blue, green or brown suction bulb that seems to magically emerge from the womb immediately after the baby and before the placenta. At least I’ve always assumed that’s where they came from because one always appeared on the warming /resuscitation table wrapped in the same towel as the baby.

These little one-piece wonders with no moving parts to malfunction or detach are all one needs to remove snot ... that is, if it needs to be removed. The problem with rubber bulbs is that if used too often they can cause irritation of the nares. However, it you can convince parents to use a bulb only when the child is experiencing some trouble breathing, this complication is usually avoided. The challenge is getting parents to ignore their natural revulsion to seeing or even hearing snot. Trying to make their child’s face a snot-free zone will make the child’s nose a bloody painful mess.

The same challenge will confront you if you suggest to parents that their child will be more comfortable if they wipe his runny nose as infrequently as possible. It seems too counterintuitive that the best option for the child is to let the snot dry on and soak it off with warm water at lunch, bedtime, and of course, just before Skyping with Grandma.

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics, including “Coping with a Picky Eater.” E-mail him at [email protected].

If you do your recreational reading during your lunch break, you might want to skip this column and save it for later in the day because I’m going to be talking about snot ... gooey, slimy, green, yellow, and even clear, runny snot. Children and snot go together like ham and eggs.

Although snot is as much a part of the normal maturation process as cutting and losing primary teeth, it suffers from a serious image problem. When we refer to a “snotty-nosed kid,” we aren’t just describing a child with an unappealing visage – we are suggesting that he has a personality problem and an unpleasant demeanor. But, this characterization is unfairly inaccurate because during the winter months, it seems that 90% of the children under the age of 3 years have runny, snotty noses. Most of them continue to be cute and have endearing personalities despite the river of mucus cascading down over their upper lips.

Adults may complain of having a “runny nose,” but they would never admit to having a “snotty nose.” Does something magically happen at puberty so that the human body no longer manufactures snot? No, it is all about appearances. Adults have learned strategies for keeping snot off their faces. They carry handkerchiefs in their pockets or wads of facial tissue stuffed up a sleeve.

But little children don’t care how they look. Like tears, snot emerges on their faces at body temperature. It doesn’t feel uncomfortable and when it drips from their upper lips and lands on their tongue, it doesn’t taste unpleasant. Little children don’t have important paperwork that might be spattered with dripping snot nor do they have computer keyboards or touch screens to be besmirched (or at least they shouldn’t have).

The fact is that adults, especially parents, don’t like the look of snot dripping from anyone’s nose. They don’t even like the sound of it gurgling around that might signal the appearance of a disgusting rivulet. I recently learned from an article in the Wall Street Journal (“Clear Baby’s Stuffy Nose,” by Laura Johannes, Feb 2, 2015) about two new products that promise parents a new tool to deal with this natural substance that they find so repulsive. Both gadgets incorporate a mouthpiece and tube with which the parent or caregiver sucks the snot out of the child’s nose into a reservoir. Although each system is fitted with a filter of sorts, I doubt you will find many nonparental caregivers logging on to watch the instructional videos.

A small study reported by one of the manufacturers claims that parents felt that their children were less congested and slept better when they used these “snotsuckers.” Of course, there was no control group. I suspect that neither apparatus would be any more effective that the old blue, green or brown suction bulb that seems to magically emerge from the womb immediately after the baby and before the placenta. At least I’ve always assumed that’s where they came from because one always appeared on the warming /resuscitation table wrapped in the same towel as the baby.

These little one-piece wonders with no moving parts to malfunction or detach are all one needs to remove snot ... that is, if it needs to be removed. The problem with rubber bulbs is that if used too often they can cause irritation of the nares. However, it you can convince parents to use a bulb only when the child is experiencing some trouble breathing, this complication is usually avoided. The challenge is getting parents to ignore their natural revulsion to seeing or even hearing snot. Trying to make their child’s face a snot-free zone will make the child’s nose a bloody painful mess.

The same challenge will confront you if you suggest to parents that their child will be more comfortable if they wipe his runny nose as infrequently as possible. It seems too counterintuitive that the best option for the child is to let the snot dry on and soak it off with warm water at lunch, bedtime, and of course, just before Skyping with Grandma.

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics, including “Coping with a Picky Eater.” E-mail him at [email protected].

References

References

Publications
Publications
Topics
Article Type
Display Headline
Snot happens
Display Headline
Snot happens
Legacy Keywords
snot, nares, bulb, runny nose, mucus, snotty-nosed kid
Legacy Keywords
snot, nares, bulb, runny nose, mucus, snotty-nosed kid
Sections
Article Source

PURLs Copyright

Inside the Article

Hand rejuvenation

Article Type
Changed
Fri, 06/11/2021 - 10:19
Display Headline
Hand rejuvenation

The three most exposed areas of the body that give away a person’s age are the face, neck, and hands. Rejuvenation of the hands is an often simple and nice addition to facial and neck aesthetic rejuvenation.

When examining aging hands, the three most prominent features are decreased volume in the interosseous spaces (leading to increased crepiness of the skin and increased show of extensor tendons), lentigines, and prominent veins. Therefore, the treatment for hands is quite simple: Restore volume, treat the pigmented lesions, and if needed, treat the prominent veins.

The anatomy of the dorsal hand can be divided into three major compartments. First, the skin, which on the dorsal hand is quite pliable. Second, the subcutaneous tissue, which consists of a loose areolar tissue where the lymphatics and veins lie. Third, beneath the subcutaneous tissue is the dorsal fascia of the hand, which is contiguous with extensor tendons and underlying compartments. It is in the subcutaneous layer (or loose areolar tissue) where fillers or fat are placed to treat volume loss.

While several fillers are currently used off label for hand rejuvenation, the Food and Drug Administration is meeting in February to consider officially approving Radiesse for this indication. Currently, hyaluronic acid (HA) fillers, calcium- hydroxylapatite (Radiesse), poly-L-lactic acid, and autologous fat are all utilized. I tend to use HAs in this location because of the reversibility, if needed, and decreased risk of nodule formation. Several techniques exist, including injecting between each tendon space vs. a bolus technique. I tend to use a bolus technique, where one or two boluses are injected while tenting the skin up to ensure injection into the correct plane and to avoid the vessels. Subsequently, the boluses are massaged into place while the patient makes a fist.

Once the interosseous spaces have been treated, the veins often appear less prominent and often don’t require direct treatment. I typically do not treat the dorsal hand veins, but sclerotherapy can be performed. Lentigines may be treated with a variety of devices including intense pulse light, Q-switched lasers, and fractionated nonablative lasers. Chemical peels and topical antipigment agents also may help to a lesser degree or also may be used for maintenance to keep the lentigines away.

Dr. Talakoub and Dr. Wesley are co-contributors to a monthly Aesthetic Dermatology column in Dermatology News. Dr. Talakoub is in private practice in McLean, Va. Dr. Wesley practices dermatology in Beverly Hills, Calif. This month’s column is by Dr. Wesley.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
hand, rejuvention, hyaluronic acid, filler, fat
Sections
Author and Disclosure Information

Author and Disclosure Information

The three most exposed areas of the body that give away a person’s age are the face, neck, and hands. Rejuvenation of the hands is an often simple and nice addition to facial and neck aesthetic rejuvenation.

When examining aging hands, the three most prominent features are decreased volume in the interosseous spaces (leading to increased crepiness of the skin and increased show of extensor tendons), lentigines, and prominent veins. Therefore, the treatment for hands is quite simple: Restore volume, treat the pigmented lesions, and if needed, treat the prominent veins.

The anatomy of the dorsal hand can be divided into three major compartments. First, the skin, which on the dorsal hand is quite pliable. Second, the subcutaneous tissue, which consists of a loose areolar tissue where the lymphatics and veins lie. Third, beneath the subcutaneous tissue is the dorsal fascia of the hand, which is contiguous with extensor tendons and underlying compartments. It is in the subcutaneous layer (or loose areolar tissue) where fillers or fat are placed to treat volume loss.

While several fillers are currently used off label for hand rejuvenation, the Food and Drug Administration is meeting in February to consider officially approving Radiesse for this indication. Currently, hyaluronic acid (HA) fillers, calcium- hydroxylapatite (Radiesse), poly-L-lactic acid, and autologous fat are all utilized. I tend to use HAs in this location because of the reversibility, if needed, and decreased risk of nodule formation. Several techniques exist, including injecting between each tendon space vs. a bolus technique. I tend to use a bolus technique, where one or two boluses are injected while tenting the skin up to ensure injection into the correct plane and to avoid the vessels. Subsequently, the boluses are massaged into place while the patient makes a fist.

Once the interosseous spaces have been treated, the veins often appear less prominent and often don’t require direct treatment. I typically do not treat the dorsal hand veins, but sclerotherapy can be performed. Lentigines may be treated with a variety of devices including intense pulse light, Q-switched lasers, and fractionated nonablative lasers. Chemical peels and topical antipigment agents also may help to a lesser degree or also may be used for maintenance to keep the lentigines away.

Dr. Talakoub and Dr. Wesley are co-contributors to a monthly Aesthetic Dermatology column in Dermatology News. Dr. Talakoub is in private practice in McLean, Va. Dr. Wesley practices dermatology in Beverly Hills, Calif. This month’s column is by Dr. Wesley.

The three most exposed areas of the body that give away a person’s age are the face, neck, and hands. Rejuvenation of the hands is an often simple and nice addition to facial and neck aesthetic rejuvenation.

When examining aging hands, the three most prominent features are decreased volume in the interosseous spaces (leading to increased crepiness of the skin and increased show of extensor tendons), lentigines, and prominent veins. Therefore, the treatment for hands is quite simple: Restore volume, treat the pigmented lesions, and if needed, treat the prominent veins.

The anatomy of the dorsal hand can be divided into three major compartments. First, the skin, which on the dorsal hand is quite pliable. Second, the subcutaneous tissue, which consists of a loose areolar tissue where the lymphatics and veins lie. Third, beneath the subcutaneous tissue is the dorsal fascia of the hand, which is contiguous with extensor tendons and underlying compartments. It is in the subcutaneous layer (or loose areolar tissue) where fillers or fat are placed to treat volume loss.

While several fillers are currently used off label for hand rejuvenation, the Food and Drug Administration is meeting in February to consider officially approving Radiesse for this indication. Currently, hyaluronic acid (HA) fillers, calcium- hydroxylapatite (Radiesse), poly-L-lactic acid, and autologous fat are all utilized. I tend to use HAs in this location because of the reversibility, if needed, and decreased risk of nodule formation. Several techniques exist, including injecting between each tendon space vs. a bolus technique. I tend to use a bolus technique, where one or two boluses are injected while tenting the skin up to ensure injection into the correct plane and to avoid the vessels. Subsequently, the boluses are massaged into place while the patient makes a fist.

Once the interosseous spaces have been treated, the veins often appear less prominent and often don’t require direct treatment. I typically do not treat the dorsal hand veins, but sclerotherapy can be performed. Lentigines may be treated with a variety of devices including intense pulse light, Q-switched lasers, and fractionated nonablative lasers. Chemical peels and topical antipigment agents also may help to a lesser degree or also may be used for maintenance to keep the lentigines away.

Dr. Talakoub and Dr. Wesley are co-contributors to a monthly Aesthetic Dermatology column in Dermatology News. Dr. Talakoub is in private practice in McLean, Va. Dr. Wesley practices dermatology in Beverly Hills, Calif. This month’s column is by Dr. Wesley.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Hand rejuvenation
Display Headline
Hand rejuvenation
Legacy Keywords
hand, rejuvention, hyaluronic acid, filler, fat
Legacy Keywords
hand, rejuvention, hyaluronic acid, filler, fat
Sections
Article Source

PURLs Copyright

Inside the Article

Treating VTE in patients with gynecologic malignancies

Article Type
Changed
Fri, 01/04/2019 - 12:49
Display Headline
Treating VTE in patients with gynecologic malignancies

Rudolph Virchow clearly demonstrated the association between malignancy and venous thromboembolic events. VTE – deep vein thrombosis and pulmonary embolism – affect between 15% and 38% of patients with gynecologic malignancies after surgery.

The rate of pulmonary embolism (PE) in this patient population can be as high as 6.8%, with the case fatality rate being 11%-12% (Obstet. Gynecol. 2012;119:155-67). Other factors associated with the development of VTE include prior VTE, older age, African American race, prolonged operative time, obesity, and prior radiation therapy (Obstet. Gynecol. 1987;69:146-50). The risk of VTE in women undergoing gynecologic surgery is quadrupled in the presence of malignancy(Obstet. Gynecol. 2006;107:666-71) and these patients are twice as likely to die from a VTE compared to matched controls (Gynecol. Oncol. 2007;106:439-45).

Additionally, cancer patients are typically older, have longer and more complex surgeries, and the presence of a pelvic mass further contributes to venous stasis (Obstet. Gynecol. 2012;119:155-67).

Although the treatment of VTE is fairly similar between patients with malignancy and those without cancer, treatment of a VTE in patients with cancer can be further complicated by higher VTE recurrence rates and increased risk of bleeding. Furthermore, issues related to the malignant disease process such as prognosis, presence and location of metastasis, and life expectancy should be taken into consideration when managing VTE in this patient population.

Generally, in the setting of an acute or recurrent VTE, initial therapy with a parenteral anticoagulant (heparin or low-molecular-weight heparins [LMWH]) should be immediately instituted in patients with a gynecologic malignancy, unless there is evidence of active bleeding or any other contraindication for the use of an anticoagulant.

Other factors associated with cancer such as immobilization, the presence of metastases, and impaired renal function with a creatinine clearance less than 30 mL/min, may increase the risk of bleeding complications but are not absolute contraindications to anticoagulation (Thromb. Haemost. 2008;100:435-9). The initial treatment phase, which last for 5-10 days, is then followed by a longer treatment phase lasting 3-6 months.

In the majority of cases, LMWH is the preferred agent for both the initial and prolonged treatment phase assuming adequate renal function. Based on evidence from a meta-analysis of 16 randomized controlled trials in cancer patients receiving initial anticoagulation for VTE, LMWH is associated with a 30% reduction in mortality without an increased risk of bleeding in comparison to unfractionated heparin (Cochrane Database. Syst. Rev. 2014;6:CD006649).

When compared with the vitamin K antagonist warfarin, LMWH appears to be associated with a significantly reduced rate of recurrent VTE (hazard ratio, 0.47; 95% confidence interval 0.32-0.71). However, this was not associated with a survival advantage (N. Engl. J. Med. 2003;349:146-53).

There are no trials comparing the different formulations of LMWH. In our practice, we routinely use the LMWH enoxaparin dosed at 1 mg/kg subcutaneously twice daily. Other well-studied LMWHs include dalteparin and tinzaparin.

LMWHs are primarily renally excreted, thus, in patients with compromised renal function, the biological half-life of the medication may be prolonged, leading to potential bleeding complications. The majority of LMWH trials excluded patients with creatinine clearance less than 30 mL/min, therefore, in patients with compromised renal function, one option would be to decrease the daily dose by as much as 50% and closely monitor antifactor XA levels. Alternatively, the use of unfractionated heparin in the acute setting followed by warfarin with close monitoring of the patient’s international normalized ratio could prove less cumbersome and ultimately safer for these patients. However, given the limitations of the currently available data we would not recommend the routine use of newer oral anticoagulation agents.

Patients with a malignancy are at increased risk for the development of a recurrent VTE even in the setting of anticoagulation. Some of the risks factors for this phenomenon include presence of central venous catheters, interruption of therapy for procedures, and immobilization. In cases of recurrent VTE, consideration should be given to extending the duration of treatment beyond the initial planned 3-6 months. Other patients that may benefit from extended therapy include those with continued immobility or active cancer burden.

LMWH is also the preferred agent for extended therapy based on very limited evidence from experimental studies suggesting that LMWH may have antineoplastic effects and thus a survival advantage. However, in the setting of a recurrent VTE, there is very limited data on which to base the choice of extended treatment. Options include switching the therapeutic agent, increasing the dose or frequency of administration, or placement of an inferior vena cava filter. Consultation with a hematologist may also be warranted in this and more complicated scenarios.

 

 

Ultimately, LMWH appears to be the best available therapy for patients with a gynecologic malignancy. However, the decision to anticoagulate should be carefully planned out, taking into consideration the individual patient’s disease burden and associated comorbidities in order to select the most appropriate treatment option.

Dr. Roque is a fellow in the gynecologic oncology program at the University of North Carolina at Chapel Hill. Dr. Clarke-Pearson is the chair and the Robert A. Ross Distinguished Professor of Obstetrics and Gynecology and a professor in the division of gynecologic oncology at the university. Dr. Roque and Dr. Clarke-Pearson said they had no relevant financial disclosures.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
venous thromboembolism, gynecologic malignancy
Sections
Author and Disclosure Information

Author and Disclosure Information

Rudolph Virchow clearly demonstrated the association between malignancy and venous thromboembolic events. VTE – deep vein thrombosis and pulmonary embolism – affect between 15% and 38% of patients with gynecologic malignancies after surgery.

The rate of pulmonary embolism (PE) in this patient population can be as high as 6.8%, with the case fatality rate being 11%-12% (Obstet. Gynecol. 2012;119:155-67). Other factors associated with the development of VTE include prior VTE, older age, African American race, prolonged operative time, obesity, and prior radiation therapy (Obstet. Gynecol. 1987;69:146-50). The risk of VTE in women undergoing gynecologic surgery is quadrupled in the presence of malignancy(Obstet. Gynecol. 2006;107:666-71) and these patients are twice as likely to die from a VTE compared to matched controls (Gynecol. Oncol. 2007;106:439-45).

Additionally, cancer patients are typically older, have longer and more complex surgeries, and the presence of a pelvic mass further contributes to venous stasis (Obstet. Gynecol. 2012;119:155-67).

Although the treatment of VTE is fairly similar between patients with malignancy and those without cancer, treatment of a VTE in patients with cancer can be further complicated by higher VTE recurrence rates and increased risk of bleeding. Furthermore, issues related to the malignant disease process such as prognosis, presence and location of metastasis, and life expectancy should be taken into consideration when managing VTE in this patient population.

Generally, in the setting of an acute or recurrent VTE, initial therapy with a parenteral anticoagulant (heparin or low-molecular-weight heparins [LMWH]) should be immediately instituted in patients with a gynecologic malignancy, unless there is evidence of active bleeding or any other contraindication for the use of an anticoagulant.

Other factors associated with cancer such as immobilization, the presence of metastases, and impaired renal function with a creatinine clearance less than 30 mL/min, may increase the risk of bleeding complications but are not absolute contraindications to anticoagulation (Thromb. Haemost. 2008;100:435-9). The initial treatment phase, which last for 5-10 days, is then followed by a longer treatment phase lasting 3-6 months.

In the majority of cases, LMWH is the preferred agent for both the initial and prolonged treatment phase assuming adequate renal function. Based on evidence from a meta-analysis of 16 randomized controlled trials in cancer patients receiving initial anticoagulation for VTE, LMWH is associated with a 30% reduction in mortality without an increased risk of bleeding in comparison to unfractionated heparin (Cochrane Database. Syst. Rev. 2014;6:CD006649).

When compared with the vitamin K antagonist warfarin, LMWH appears to be associated with a significantly reduced rate of recurrent VTE (hazard ratio, 0.47; 95% confidence interval 0.32-0.71). However, this was not associated with a survival advantage (N. Engl. J. Med. 2003;349:146-53).

There are no trials comparing the different formulations of LMWH. In our practice, we routinely use the LMWH enoxaparin dosed at 1 mg/kg subcutaneously twice daily. Other well-studied LMWHs include dalteparin and tinzaparin.

LMWHs are primarily renally excreted, thus, in patients with compromised renal function, the biological half-life of the medication may be prolonged, leading to potential bleeding complications. The majority of LMWH trials excluded patients with creatinine clearance less than 30 mL/min, therefore, in patients with compromised renal function, one option would be to decrease the daily dose by as much as 50% and closely monitor antifactor XA levels. Alternatively, the use of unfractionated heparin in the acute setting followed by warfarin with close monitoring of the patient’s international normalized ratio could prove less cumbersome and ultimately safer for these patients. However, given the limitations of the currently available data we would not recommend the routine use of newer oral anticoagulation agents.

Patients with a malignancy are at increased risk for the development of a recurrent VTE even in the setting of anticoagulation. Some of the risks factors for this phenomenon include presence of central venous catheters, interruption of therapy for procedures, and immobilization. In cases of recurrent VTE, consideration should be given to extending the duration of treatment beyond the initial planned 3-6 months. Other patients that may benefit from extended therapy include those with continued immobility or active cancer burden.

LMWH is also the preferred agent for extended therapy based on very limited evidence from experimental studies suggesting that LMWH may have antineoplastic effects and thus a survival advantage. However, in the setting of a recurrent VTE, there is very limited data on which to base the choice of extended treatment. Options include switching the therapeutic agent, increasing the dose or frequency of administration, or placement of an inferior vena cava filter. Consultation with a hematologist may also be warranted in this and more complicated scenarios.

 

 

Ultimately, LMWH appears to be the best available therapy for patients with a gynecologic malignancy. However, the decision to anticoagulate should be carefully planned out, taking into consideration the individual patient’s disease burden and associated comorbidities in order to select the most appropriate treatment option.

Dr. Roque is a fellow in the gynecologic oncology program at the University of North Carolina at Chapel Hill. Dr. Clarke-Pearson is the chair and the Robert A. Ross Distinguished Professor of Obstetrics and Gynecology and a professor in the division of gynecologic oncology at the university. Dr. Roque and Dr. Clarke-Pearson said they had no relevant financial disclosures.

Rudolph Virchow clearly demonstrated the association between malignancy and venous thromboembolic events. VTE – deep vein thrombosis and pulmonary embolism – affect between 15% and 38% of patients with gynecologic malignancies after surgery.

The rate of pulmonary embolism (PE) in this patient population can be as high as 6.8%, with the case fatality rate being 11%-12% (Obstet. Gynecol. 2012;119:155-67). Other factors associated with the development of VTE include prior VTE, older age, African American race, prolonged operative time, obesity, and prior radiation therapy (Obstet. Gynecol. 1987;69:146-50). The risk of VTE in women undergoing gynecologic surgery is quadrupled in the presence of malignancy(Obstet. Gynecol. 2006;107:666-71) and these patients are twice as likely to die from a VTE compared to matched controls (Gynecol. Oncol. 2007;106:439-45).

Additionally, cancer patients are typically older, have longer and more complex surgeries, and the presence of a pelvic mass further contributes to venous stasis (Obstet. Gynecol. 2012;119:155-67).

Although the treatment of VTE is fairly similar between patients with malignancy and those without cancer, treatment of a VTE in patients with cancer can be further complicated by higher VTE recurrence rates and increased risk of bleeding. Furthermore, issues related to the malignant disease process such as prognosis, presence and location of metastasis, and life expectancy should be taken into consideration when managing VTE in this patient population.

Generally, in the setting of an acute or recurrent VTE, initial therapy with a parenteral anticoagulant (heparin or low-molecular-weight heparins [LMWH]) should be immediately instituted in patients with a gynecologic malignancy, unless there is evidence of active bleeding or any other contraindication for the use of an anticoagulant.

Other factors associated with cancer such as immobilization, the presence of metastases, and impaired renal function with a creatinine clearance less than 30 mL/min, may increase the risk of bleeding complications but are not absolute contraindications to anticoagulation (Thromb. Haemost. 2008;100:435-9). The initial treatment phase, which last for 5-10 days, is then followed by a longer treatment phase lasting 3-6 months.

In the majority of cases, LMWH is the preferred agent for both the initial and prolonged treatment phase assuming adequate renal function. Based on evidence from a meta-analysis of 16 randomized controlled trials in cancer patients receiving initial anticoagulation for VTE, LMWH is associated with a 30% reduction in mortality without an increased risk of bleeding in comparison to unfractionated heparin (Cochrane Database. Syst. Rev. 2014;6:CD006649).

When compared with the vitamin K antagonist warfarin, LMWH appears to be associated with a significantly reduced rate of recurrent VTE (hazard ratio, 0.47; 95% confidence interval 0.32-0.71). However, this was not associated with a survival advantage (N. Engl. J. Med. 2003;349:146-53).

There are no trials comparing the different formulations of LMWH. In our practice, we routinely use the LMWH enoxaparin dosed at 1 mg/kg subcutaneously twice daily. Other well-studied LMWHs include dalteparin and tinzaparin.

LMWHs are primarily renally excreted, thus, in patients with compromised renal function, the biological half-life of the medication may be prolonged, leading to potential bleeding complications. The majority of LMWH trials excluded patients with creatinine clearance less than 30 mL/min, therefore, in patients with compromised renal function, one option would be to decrease the daily dose by as much as 50% and closely monitor antifactor XA levels. Alternatively, the use of unfractionated heparin in the acute setting followed by warfarin with close monitoring of the patient’s international normalized ratio could prove less cumbersome and ultimately safer for these patients. However, given the limitations of the currently available data we would not recommend the routine use of newer oral anticoagulation agents.

Patients with a malignancy are at increased risk for the development of a recurrent VTE even in the setting of anticoagulation. Some of the risks factors for this phenomenon include presence of central venous catheters, interruption of therapy for procedures, and immobilization. In cases of recurrent VTE, consideration should be given to extending the duration of treatment beyond the initial planned 3-6 months. Other patients that may benefit from extended therapy include those with continued immobility or active cancer burden.

LMWH is also the preferred agent for extended therapy based on very limited evidence from experimental studies suggesting that LMWH may have antineoplastic effects and thus a survival advantage. However, in the setting of a recurrent VTE, there is very limited data on which to base the choice of extended treatment. Options include switching the therapeutic agent, increasing the dose or frequency of administration, or placement of an inferior vena cava filter. Consultation with a hematologist may also be warranted in this and more complicated scenarios.

 

 

Ultimately, LMWH appears to be the best available therapy for patients with a gynecologic malignancy. However, the decision to anticoagulate should be carefully planned out, taking into consideration the individual patient’s disease burden and associated comorbidities in order to select the most appropriate treatment option.

Dr. Roque is a fellow in the gynecologic oncology program at the University of North Carolina at Chapel Hill. Dr. Clarke-Pearson is the chair and the Robert A. Ross Distinguished Professor of Obstetrics and Gynecology and a professor in the division of gynecologic oncology at the university. Dr. Roque and Dr. Clarke-Pearson said they had no relevant financial disclosures.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Treating VTE in patients with gynecologic malignancies
Display Headline
Treating VTE in patients with gynecologic malignancies
Legacy Keywords
venous thromboembolism, gynecologic malignancy
Legacy Keywords
venous thromboembolism, gynecologic malignancy
Sections
Article Source

PURLs Copyright

Inside the Article

The buzz about noise-induced hearing loss

Article Type
Changed
Fri, 01/18/2019 - 14:25
Display Headline
The buzz about noise-induced hearing loss

As you know all too well, technology is transforming the lives of today’s children in seemingly endless ways. While much of its impact is still unknown or debatable, one straightforward yet underappreciated issue is the consequences of misuse of personal audio technology on children’s hearing.

It is not uncommon today to see even young toddlers expertly navigating tablets, cell phones, and MP3 players. Many children and adolescents will wear accompanying ear buds or headphones as they play games, listen to music, or watch movies on these devices. Unfortunately, they often listen at volumes that are too loud, for too long. These habits have the potential to cause noise-induced hearing loss.

Dr. Judith L. Page

Research has suggested such hearing loss is occurring with more frequency – and at younger ages. A 2010 study in the Journal of the American Medical Association revealed one in five U.S. adolescents suffers from hearing loss of some sort – an increase of 31% since the late 1980s/early 1990s. The authors of the study noted that some risk factors, such as loud sound exposure from music listening, may be of particular importance to development of hearing loss in young people (JAMA 2010;304:772-8.).

Although a majority of parents are worried about this issue, it doesn’t always lead them to take action. In a poll of parents, commissioned by the American Speech-Language-Hearing Association (ASHA), 84% of respondents said they were concerned that misuse of personal audio technology was damaging the hearing of children in general – and 75% said teaching children how to use this technology safely should be a major public health priority. Yet only half had discussed safe listening with their own children.

Concern has become substantial enough that the World Health Organization (WHO) in March 2015 is launching a public education campaign called “Make Listening Safe,” focused on preventing noise-induced hearing loss in children.

Hearing is critical to speech and language development, communication, and learning. Hearing loss affects children in four major ways, potentially causing:

• Delays or deficits in the development of receptive and expressive communication skills (speech and language).

• Reduced academic achievement because of learning problems resulting from language deficits.

• Social isolation and poor self-concept, often resulting from communication difficulties.

• Limited vocational choices because of academic and communication deficits.

Even a so-called minor hearing loss has serious effects. One study showed that children with mild hearing loss miss 25%-50% of speech in the classroom. In addition to the obvious implications for learning, these children also may be inappropriately labeled as having a behavior problem.

You can play a key role in educating parents and children about the potential health risk of hearing loss from misuse of technology – and how to enjoy their devices responsibly. Here are some simple steps to pass along:

• Keep the volume down – a good guide is half volume.

• Limit listening time and take “quiet breaks.”

• Model good listening habits for your children.

ASHA’s Listen to Your Buds campaign (www.listentoyourbuds.org) offers educational resources that you, parents, and others can use. The campaign recently was tapped by WHO to be a partner in its current effort. One of the Buds’ main tactics is “safe listening concerts,” which have been held in roughly 60 schools to date. If you are interested in receiving free information, contact [email protected].

Dr. Page, a certified speech language pathologist, is associate professor in the division of communication sciences and disorders at the University of Kentucky, Lexington, and president of the American Speech-Language-Hearing Association, Rockville, Md. Dr. Page said she had no relevant financial disclosures.

References

Author and Disclosure Information

Publications
Legacy Keywords
noise-induced hearing loss, earphones, concerts
Sections
Author and Disclosure Information

Author and Disclosure Information

As you know all too well, technology is transforming the lives of today’s children in seemingly endless ways. While much of its impact is still unknown or debatable, one straightforward yet underappreciated issue is the consequences of misuse of personal audio technology on children’s hearing.

It is not uncommon today to see even young toddlers expertly navigating tablets, cell phones, and MP3 players. Many children and adolescents will wear accompanying ear buds or headphones as they play games, listen to music, or watch movies on these devices. Unfortunately, they often listen at volumes that are too loud, for too long. These habits have the potential to cause noise-induced hearing loss.

Dr. Judith L. Page

Research has suggested such hearing loss is occurring with more frequency – and at younger ages. A 2010 study in the Journal of the American Medical Association revealed one in five U.S. adolescents suffers from hearing loss of some sort – an increase of 31% since the late 1980s/early 1990s. The authors of the study noted that some risk factors, such as loud sound exposure from music listening, may be of particular importance to development of hearing loss in young people (JAMA 2010;304:772-8.).

Although a majority of parents are worried about this issue, it doesn’t always lead them to take action. In a poll of parents, commissioned by the American Speech-Language-Hearing Association (ASHA), 84% of respondents said they were concerned that misuse of personal audio technology was damaging the hearing of children in general – and 75% said teaching children how to use this technology safely should be a major public health priority. Yet only half had discussed safe listening with their own children.

Concern has become substantial enough that the World Health Organization (WHO) in March 2015 is launching a public education campaign called “Make Listening Safe,” focused on preventing noise-induced hearing loss in children.

Hearing is critical to speech and language development, communication, and learning. Hearing loss affects children in four major ways, potentially causing:

• Delays or deficits in the development of receptive and expressive communication skills (speech and language).

• Reduced academic achievement because of learning problems resulting from language deficits.

• Social isolation and poor self-concept, often resulting from communication difficulties.

• Limited vocational choices because of academic and communication deficits.

Even a so-called minor hearing loss has serious effects. One study showed that children with mild hearing loss miss 25%-50% of speech in the classroom. In addition to the obvious implications for learning, these children also may be inappropriately labeled as having a behavior problem.

You can play a key role in educating parents and children about the potential health risk of hearing loss from misuse of technology – and how to enjoy their devices responsibly. Here are some simple steps to pass along:

• Keep the volume down – a good guide is half volume.

• Limit listening time and take “quiet breaks.”

• Model good listening habits for your children.

ASHA’s Listen to Your Buds campaign (www.listentoyourbuds.org) offers educational resources that you, parents, and others can use. The campaign recently was tapped by WHO to be a partner in its current effort. One of the Buds’ main tactics is “safe listening concerts,” which have been held in roughly 60 schools to date. If you are interested in receiving free information, contact [email protected].

Dr. Page, a certified speech language pathologist, is associate professor in the division of communication sciences and disorders at the University of Kentucky, Lexington, and president of the American Speech-Language-Hearing Association, Rockville, Md. Dr. Page said she had no relevant financial disclosures.

As you know all too well, technology is transforming the lives of today’s children in seemingly endless ways. While much of its impact is still unknown or debatable, one straightforward yet underappreciated issue is the consequences of misuse of personal audio technology on children’s hearing.

It is not uncommon today to see even young toddlers expertly navigating tablets, cell phones, and MP3 players. Many children and adolescents will wear accompanying ear buds or headphones as they play games, listen to music, or watch movies on these devices. Unfortunately, they often listen at volumes that are too loud, for too long. These habits have the potential to cause noise-induced hearing loss.

Dr. Judith L. Page

Research has suggested such hearing loss is occurring with more frequency – and at younger ages. A 2010 study in the Journal of the American Medical Association revealed one in five U.S. adolescents suffers from hearing loss of some sort – an increase of 31% since the late 1980s/early 1990s. The authors of the study noted that some risk factors, such as loud sound exposure from music listening, may be of particular importance to development of hearing loss in young people (JAMA 2010;304:772-8.).

Although a majority of parents are worried about this issue, it doesn’t always lead them to take action. In a poll of parents, commissioned by the American Speech-Language-Hearing Association (ASHA), 84% of respondents said they were concerned that misuse of personal audio technology was damaging the hearing of children in general – and 75% said teaching children how to use this technology safely should be a major public health priority. Yet only half had discussed safe listening with their own children.

Concern has become substantial enough that the World Health Organization (WHO) in March 2015 is launching a public education campaign called “Make Listening Safe,” focused on preventing noise-induced hearing loss in children.

Hearing is critical to speech and language development, communication, and learning. Hearing loss affects children in four major ways, potentially causing:

• Delays or deficits in the development of receptive and expressive communication skills (speech and language).

• Reduced academic achievement because of learning problems resulting from language deficits.

• Social isolation and poor self-concept, often resulting from communication difficulties.

• Limited vocational choices because of academic and communication deficits.

Even a so-called minor hearing loss has serious effects. One study showed that children with mild hearing loss miss 25%-50% of speech in the classroom. In addition to the obvious implications for learning, these children also may be inappropriately labeled as having a behavior problem.

You can play a key role in educating parents and children about the potential health risk of hearing loss from misuse of technology – and how to enjoy their devices responsibly. Here are some simple steps to pass along:

• Keep the volume down – a good guide is half volume.

• Limit listening time and take “quiet breaks.”

• Model good listening habits for your children.

ASHA’s Listen to Your Buds campaign (www.listentoyourbuds.org) offers educational resources that you, parents, and others can use. The campaign recently was tapped by WHO to be a partner in its current effort. One of the Buds’ main tactics is “safe listening concerts,” which have been held in roughly 60 schools to date. If you are interested in receiving free information, contact [email protected].

Dr. Page, a certified speech language pathologist, is associate professor in the division of communication sciences and disorders at the University of Kentucky, Lexington, and president of the American Speech-Language-Hearing Association, Rockville, Md. Dr. Page said she had no relevant financial disclosures.

References

References

Publications
Publications
Article Type
Display Headline
The buzz about noise-induced hearing loss
Display Headline
The buzz about noise-induced hearing loss
Legacy Keywords
noise-induced hearing loss, earphones, concerts
Legacy Keywords
noise-induced hearing loss, earphones, concerts
Sections
Article Source

PURLs Copyright

Inside the Article

Kaempferol

Article Type
Changed
Mon, 01/14/2019 - 09:09
Display Headline
Kaempferol

Kaempferol (3,5,7,4’-tetrahydroxyflavone; C15H10O6) is among the natural flavonols found in green tea, broccoli, cabbage, kale, endive, beans, leeks, tomatoes, grapes, apples, grapefruit, berries, and propolis, as well as myriad other plant sources, including Brassica and species (J. Agric. Food Chem. 2006;54:2951-6; Cancer Prev. Res. (Phila) 2014;7:958-67; Biochem. Pharmacol. 2010;80:2042-9; Chem. Pharm. Bull. (Tokyo) 2012;60:1171-5; J. Eur. Acad. Dermatol. Venereol. 2013 June 27 [doi:10.1111/jdv.12204]).

It is one of the most commonly found dietary flavonoids and is also present in beer, particularly hops (Carcinogenesis 2010;31:1338-43; J. Eur. Acad. Dermatol. Venereol. 2013 June 27 [doi:10.1111/jdv.12204]). Significantly, kaempferol is known to exhibit anticancer, anti-inflammatory, antioxidant, cytoprotective, and antiapoptotic activity (Cancer Prev. Res. (Phila) 2014;7:958-67; Biochem. Pharmacol. 2010;80:2042-9; Exp. Mol. Med. 2008;40:208-19), and is believed to play a role in protecting plants from ultraviolet (UV)-induced damage (J. Agric. Food Chem. 2012;60:6966-76).

Skin protection: antioxidant and anti-inflammatory activity

Among 35 flavonoids tested by Cos et al. in 2001 for lipid peroxidation-inhibiting activity, kaempferol was identified as having the highest antioxidant selectivity index (Planta Med. 2001;67:515-9).

Work by Kim et al. in 2002 revealed that four kaempferol glycosides are key active ingredients in the flowers of Prunus persica, which has long been used in traditional Chinese medicine to treat skin disorders (J. Cosmet. Sci. 2002;53:27-34). Kim and colleagues have also shown in animal studies that the topical application of P. persica may be effective at thwarting UVB-induced skin damage (J. Cosmet. Sci. 2002;53:27-34).

In addition, kaempferol is a key component in Punica granatum, which has been found to act as an effective protector against UVB-induced photodamage and aging in cultured skin fibroblasts (Int. J. Dermatol. 2010;49:276-82).

In various tests on the effects of natural flavonoids on matrix metalloproteinase (MMP)-1 activity and expression, Lim et al. reported in 2007 that kaempferol and quercetin potently inhibited recombinant human MMP-1, and both flavonols along with apigenin and wogonin were found to be strong inhibitors of MMP-1 induction in 12-O-tetradecanoylphorbol-13-acetate–treated human dermal fibroblasts. All four flavonoids also suppressed the activation of activator protein (AP)-1. Kaempferol also hindered p38 mitogen-activated protein kinase c-Jun N-terminal kinase (JNK) activation. The investigators concluded that kaempferol is among the flavonoids or plant extracts containing them that may be useful as an agent to protect against photoaging and to treat some cutaneous inflammatory conditions (Planta Med. 2007;73:1267-74).

In 2010, Park et al. demonstrated that kaempferol alleviated burn injuries in mice and that expression of tumor necrosis factor–alpha (TNF-alpha) induced by burn injuries was reduced by kaempferol. They concluded that their findings suggest the possible application of kaempferol to treat thermal burn–induced skin injuries (BMB Rep. 2010;43:46-51).

Anti-inflammatory as well as depigmenting activity was found by Rho et al. in 2011 to be associated with kaempferol and kaempferol rhamnosides isolated from Hibiscus cannabinus (Molecules 2011;16:3338-44).

In 2014, Kim et al. found that extracts of Aceriphyllum rossii (native to Korea and China) and its active constituents, quercetin and kaempferol, blocked secretion of beta-hexosaminidase and histamine; lowered the production and mRNA expression of interleukin-4 and TNF-alpha; and reduced prostaglandin E2 and leukotriene B4 synthesis as well as the expression of cyclooxygenase-2 (COX-2) and 5-lipoxygenase. These and other findings led the investigators to conclude that A. rossii and its active ingredients kaempferol and quercetin may be effective agents for the treatment of immediate-type hypersensitivity (J. Agric. Food Chem. 2014;62:3750-8).

Anticancer activity

Lee et al. reported in 2010 that the inhibition by kaempferol of phosphatidylinositol 3-kinase (PI3K) activity, a key factor in carcinogenesis, and its concomitant effects may account for the chemopreventive activity of the flavonol (Carcinogenesis 2010;31:1338-43).

At the end of that year, Lee et al. found that kaempferol inhibited UVB-induced COX-2 protein expression in mouse skin epidermal JB6 P+ cells, by blocking Src kinase activity and attenuated the UVB-induced transcriptional activities of COX-2 gene and the transcription factor AP-1. They concluded that kaempferol exerts robust chemopreventive activity against skin cancer by suppressing Src (Biochem. Pharmacol. 2010;80:2042-9).

In 2014, Yao et al. found that kaempferol acted as a safe and potent inhibitor of solar ultraviolet-induced mouse skin carcinogenesis that acted by targeting RSK2 and MSK1 (Cancer Prev. Res. (Phila) 2014;7:958-67).

Significantly, in terms of topical delivery, Chao et al. recently showed that submicron emulsions are effective carriers for the transdermal delivery of kaempferol (Chem. Pharm. Bull. (Tokyo) 2012;60:1171-5).

Conclusion

Kaempferol is one among the many natural flavonols found to exert significant salutary effects. Evidence suggests reasons for confidence that kaempferol can play a role in skin health. More research is necessary to determine the effectiveness of topical products intended to harness the benefits of this flavonoid as proper formulation is challenging.

 

 

Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in the Design District in Miami. She founded the Cosmetic Dermatology Center at the University of Miami in 1997. Dr. Baumann wrote the textbook, “Cosmetic Dermatology: Principles and Practice” (New York: McGraw-Hill, 2002), and a book for consumers, “The Skin Type Solution” (New York: Bantam Dell, 2006). She has contributed to the Cosmeceutical Critique column in Dermatology News since January 2001. Her latest book, “Cosmeceuticals and Cosmetic Ingredients,” was published in November 2014. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Evolus, Galderma, GlaxoSmithKline, Kythera, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Topix Pharmaceuticals, and Unilever.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
Kaempferol
Sections
Author and Disclosure Information

Author and Disclosure Information

Kaempferol (3,5,7,4’-tetrahydroxyflavone; C15H10O6) is among the natural flavonols found in green tea, broccoli, cabbage, kale, endive, beans, leeks, tomatoes, grapes, apples, grapefruit, berries, and propolis, as well as myriad other plant sources, including Brassica and species (J. Agric. Food Chem. 2006;54:2951-6; Cancer Prev. Res. (Phila) 2014;7:958-67; Biochem. Pharmacol. 2010;80:2042-9; Chem. Pharm. Bull. (Tokyo) 2012;60:1171-5; J. Eur. Acad. Dermatol. Venereol. 2013 June 27 [doi:10.1111/jdv.12204]).

It is one of the most commonly found dietary flavonoids and is also present in beer, particularly hops (Carcinogenesis 2010;31:1338-43; J. Eur. Acad. Dermatol. Venereol. 2013 June 27 [doi:10.1111/jdv.12204]). Significantly, kaempferol is known to exhibit anticancer, anti-inflammatory, antioxidant, cytoprotective, and antiapoptotic activity (Cancer Prev. Res. (Phila) 2014;7:958-67; Biochem. Pharmacol. 2010;80:2042-9; Exp. Mol. Med. 2008;40:208-19), and is believed to play a role in protecting plants from ultraviolet (UV)-induced damage (J. Agric. Food Chem. 2012;60:6966-76).

Skin protection: antioxidant and anti-inflammatory activity

Among 35 flavonoids tested by Cos et al. in 2001 for lipid peroxidation-inhibiting activity, kaempferol was identified as having the highest antioxidant selectivity index (Planta Med. 2001;67:515-9).

Work by Kim et al. in 2002 revealed that four kaempferol glycosides are key active ingredients in the flowers of Prunus persica, which has long been used in traditional Chinese medicine to treat skin disorders (J. Cosmet. Sci. 2002;53:27-34). Kim and colleagues have also shown in animal studies that the topical application of P. persica may be effective at thwarting UVB-induced skin damage (J. Cosmet. Sci. 2002;53:27-34).

In addition, kaempferol is a key component in Punica granatum, which has been found to act as an effective protector against UVB-induced photodamage and aging in cultured skin fibroblasts (Int. J. Dermatol. 2010;49:276-82).

In various tests on the effects of natural flavonoids on matrix metalloproteinase (MMP)-1 activity and expression, Lim et al. reported in 2007 that kaempferol and quercetin potently inhibited recombinant human MMP-1, and both flavonols along with apigenin and wogonin were found to be strong inhibitors of MMP-1 induction in 12-O-tetradecanoylphorbol-13-acetate–treated human dermal fibroblasts. All four flavonoids also suppressed the activation of activator protein (AP)-1. Kaempferol also hindered p38 mitogen-activated protein kinase c-Jun N-terminal kinase (JNK) activation. The investigators concluded that kaempferol is among the flavonoids or plant extracts containing them that may be useful as an agent to protect against photoaging and to treat some cutaneous inflammatory conditions (Planta Med. 2007;73:1267-74).

In 2010, Park et al. demonstrated that kaempferol alleviated burn injuries in mice and that expression of tumor necrosis factor–alpha (TNF-alpha) induced by burn injuries was reduced by kaempferol. They concluded that their findings suggest the possible application of kaempferol to treat thermal burn–induced skin injuries (BMB Rep. 2010;43:46-51).

Anti-inflammatory as well as depigmenting activity was found by Rho et al. in 2011 to be associated with kaempferol and kaempferol rhamnosides isolated from Hibiscus cannabinus (Molecules 2011;16:3338-44).

In 2014, Kim et al. found that extracts of Aceriphyllum rossii (native to Korea and China) and its active constituents, quercetin and kaempferol, blocked secretion of beta-hexosaminidase and histamine; lowered the production and mRNA expression of interleukin-4 and TNF-alpha; and reduced prostaglandin E2 and leukotriene B4 synthesis as well as the expression of cyclooxygenase-2 (COX-2) and 5-lipoxygenase. These and other findings led the investigators to conclude that A. rossii and its active ingredients kaempferol and quercetin may be effective agents for the treatment of immediate-type hypersensitivity (J. Agric. Food Chem. 2014;62:3750-8).

Anticancer activity

Lee et al. reported in 2010 that the inhibition by kaempferol of phosphatidylinositol 3-kinase (PI3K) activity, a key factor in carcinogenesis, and its concomitant effects may account for the chemopreventive activity of the flavonol (Carcinogenesis 2010;31:1338-43).

At the end of that year, Lee et al. found that kaempferol inhibited UVB-induced COX-2 protein expression in mouse skin epidermal JB6 P+ cells, by blocking Src kinase activity and attenuated the UVB-induced transcriptional activities of COX-2 gene and the transcription factor AP-1. They concluded that kaempferol exerts robust chemopreventive activity against skin cancer by suppressing Src (Biochem. Pharmacol. 2010;80:2042-9).

In 2014, Yao et al. found that kaempferol acted as a safe and potent inhibitor of solar ultraviolet-induced mouse skin carcinogenesis that acted by targeting RSK2 and MSK1 (Cancer Prev. Res. (Phila) 2014;7:958-67).

Significantly, in terms of topical delivery, Chao et al. recently showed that submicron emulsions are effective carriers for the transdermal delivery of kaempferol (Chem. Pharm. Bull. (Tokyo) 2012;60:1171-5).

Conclusion

Kaempferol is one among the many natural flavonols found to exert significant salutary effects. Evidence suggests reasons for confidence that kaempferol can play a role in skin health. More research is necessary to determine the effectiveness of topical products intended to harness the benefits of this flavonoid as proper formulation is challenging.

 

 

Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in the Design District in Miami. She founded the Cosmetic Dermatology Center at the University of Miami in 1997. Dr. Baumann wrote the textbook, “Cosmetic Dermatology: Principles and Practice” (New York: McGraw-Hill, 2002), and a book for consumers, “The Skin Type Solution” (New York: Bantam Dell, 2006). She has contributed to the Cosmeceutical Critique column in Dermatology News since January 2001. Her latest book, “Cosmeceuticals and Cosmetic Ingredients,” was published in November 2014. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Evolus, Galderma, GlaxoSmithKline, Kythera, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Topix Pharmaceuticals, and Unilever.

Kaempferol (3,5,7,4’-tetrahydroxyflavone; C15H10O6) is among the natural flavonols found in green tea, broccoli, cabbage, kale, endive, beans, leeks, tomatoes, grapes, apples, grapefruit, berries, and propolis, as well as myriad other plant sources, including Brassica and species (J. Agric. Food Chem. 2006;54:2951-6; Cancer Prev. Res. (Phila) 2014;7:958-67; Biochem. Pharmacol. 2010;80:2042-9; Chem. Pharm. Bull. (Tokyo) 2012;60:1171-5; J. Eur. Acad. Dermatol. Venereol. 2013 June 27 [doi:10.1111/jdv.12204]).

It is one of the most commonly found dietary flavonoids and is also present in beer, particularly hops (Carcinogenesis 2010;31:1338-43; J. Eur. Acad. Dermatol. Venereol. 2013 June 27 [doi:10.1111/jdv.12204]). Significantly, kaempferol is known to exhibit anticancer, anti-inflammatory, antioxidant, cytoprotective, and antiapoptotic activity (Cancer Prev. Res. (Phila) 2014;7:958-67; Biochem. Pharmacol. 2010;80:2042-9; Exp. Mol. Med. 2008;40:208-19), and is believed to play a role in protecting plants from ultraviolet (UV)-induced damage (J. Agric. Food Chem. 2012;60:6966-76).

Skin protection: antioxidant and anti-inflammatory activity

Among 35 flavonoids tested by Cos et al. in 2001 for lipid peroxidation-inhibiting activity, kaempferol was identified as having the highest antioxidant selectivity index (Planta Med. 2001;67:515-9).

Work by Kim et al. in 2002 revealed that four kaempferol glycosides are key active ingredients in the flowers of Prunus persica, which has long been used in traditional Chinese medicine to treat skin disorders (J. Cosmet. Sci. 2002;53:27-34). Kim and colleagues have also shown in animal studies that the topical application of P. persica may be effective at thwarting UVB-induced skin damage (J. Cosmet. Sci. 2002;53:27-34).

In addition, kaempferol is a key component in Punica granatum, which has been found to act as an effective protector against UVB-induced photodamage and aging in cultured skin fibroblasts (Int. J. Dermatol. 2010;49:276-82).

In various tests on the effects of natural flavonoids on matrix metalloproteinase (MMP)-1 activity and expression, Lim et al. reported in 2007 that kaempferol and quercetin potently inhibited recombinant human MMP-1, and both flavonols along with apigenin and wogonin were found to be strong inhibitors of MMP-1 induction in 12-O-tetradecanoylphorbol-13-acetate–treated human dermal fibroblasts. All four flavonoids also suppressed the activation of activator protein (AP)-1. Kaempferol also hindered p38 mitogen-activated protein kinase c-Jun N-terminal kinase (JNK) activation. The investigators concluded that kaempferol is among the flavonoids or plant extracts containing them that may be useful as an agent to protect against photoaging and to treat some cutaneous inflammatory conditions (Planta Med. 2007;73:1267-74).

In 2010, Park et al. demonstrated that kaempferol alleviated burn injuries in mice and that expression of tumor necrosis factor–alpha (TNF-alpha) induced by burn injuries was reduced by kaempferol. They concluded that their findings suggest the possible application of kaempferol to treat thermal burn–induced skin injuries (BMB Rep. 2010;43:46-51).

Anti-inflammatory as well as depigmenting activity was found by Rho et al. in 2011 to be associated with kaempferol and kaempferol rhamnosides isolated from Hibiscus cannabinus (Molecules 2011;16:3338-44).

In 2014, Kim et al. found that extracts of Aceriphyllum rossii (native to Korea and China) and its active constituents, quercetin and kaempferol, blocked secretion of beta-hexosaminidase and histamine; lowered the production and mRNA expression of interleukin-4 and TNF-alpha; and reduced prostaglandin E2 and leukotriene B4 synthesis as well as the expression of cyclooxygenase-2 (COX-2) and 5-lipoxygenase. These and other findings led the investigators to conclude that A. rossii and its active ingredients kaempferol and quercetin may be effective agents for the treatment of immediate-type hypersensitivity (J. Agric. Food Chem. 2014;62:3750-8).

Anticancer activity

Lee et al. reported in 2010 that the inhibition by kaempferol of phosphatidylinositol 3-kinase (PI3K) activity, a key factor in carcinogenesis, and its concomitant effects may account for the chemopreventive activity of the flavonol (Carcinogenesis 2010;31:1338-43).

At the end of that year, Lee et al. found that kaempferol inhibited UVB-induced COX-2 protein expression in mouse skin epidermal JB6 P+ cells, by blocking Src kinase activity and attenuated the UVB-induced transcriptional activities of COX-2 gene and the transcription factor AP-1. They concluded that kaempferol exerts robust chemopreventive activity against skin cancer by suppressing Src (Biochem. Pharmacol. 2010;80:2042-9).

In 2014, Yao et al. found that kaempferol acted as a safe and potent inhibitor of solar ultraviolet-induced mouse skin carcinogenesis that acted by targeting RSK2 and MSK1 (Cancer Prev. Res. (Phila) 2014;7:958-67).

Significantly, in terms of topical delivery, Chao et al. recently showed that submicron emulsions are effective carriers for the transdermal delivery of kaempferol (Chem. Pharm. Bull. (Tokyo) 2012;60:1171-5).

Conclusion

Kaempferol is one among the many natural flavonols found to exert significant salutary effects. Evidence suggests reasons for confidence that kaempferol can play a role in skin health. More research is necessary to determine the effectiveness of topical products intended to harness the benefits of this flavonoid as proper formulation is challenging.

 

 

Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in the Design District in Miami. She founded the Cosmetic Dermatology Center at the University of Miami in 1997. Dr. Baumann wrote the textbook, “Cosmetic Dermatology: Principles and Practice” (New York: McGraw-Hill, 2002), and a book for consumers, “The Skin Type Solution” (New York: Bantam Dell, 2006). She has contributed to the Cosmeceutical Critique column in Dermatology News since January 2001. Her latest book, “Cosmeceuticals and Cosmetic Ingredients,” was published in November 2014. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Evolus, Galderma, GlaxoSmithKline, Kythera, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Topix Pharmaceuticals, and Unilever.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Kaempferol
Display Headline
Kaempferol
Legacy Keywords
Kaempferol
Legacy Keywords
Kaempferol
Sections
Article Source

PURLs Copyright

Inside the Article